EUCTR2021-001342-34-DK进行中（未招募）1 期
ow-dose glucagon for Prevention of Exercise-Induced Hypoglycemia in People with Type 1 Diabetes
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •T1D = 2 years
- •Use of insulin pump or MDI therapy for = 6 months
- •Current use of insulin aspart
- •HbA1c = 70mmol/mol (8.5%)
- •Body mass index (BMI) = 30 kg/m2
- •Performs exercise = 1 time per week
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period and within 30 days prior to study start
- •Professional athletes or highly active individuals (= 5 hours of exercise per week)
- •Known or suspected allergies to glucagon or related products
- •History of hypersensitivity or allergic reaction to glucagon or lactose
- •Allergy to the patch of the CGM devices
- •Patients with pheochromocytoma, insulinoma or gastroparesis
- •Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (methods are considered adequate for study enrollment for females: an intrauterine device, hormonal contraception (birth control pills, implant, patch, vaginal ring or injection), a single partner who is sterile or infertile, or sexual abstinence. Contraception is required throughout the study duration. Sterilized or postmenopausal women (>12 months since last period) are not required to use contraception)
- •Inability to understand the individual information and to give informed consent
- •Current participation in another clinical trial that, in the judgment of the investigator, will compromise the results of the study or the safety of the subject
- •Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation
研究者
相似试验
已完成
不适用
Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 DiabetesType 1 DiabetesHypoglycemiaNCT05076292Steno Diabetes Center Copenhagen22
已完成
2 期
The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 DiabetesDiabetes Mellitus, Type 1NCT02660242Jaeb Center for Health Research16
进行中（未招募）
1 期
Dapagliflozin during exercise for the prevention of Hypoglycaemia in Type 1 diabetesType 1 diabetes mellitusMedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-003911-21-GBniversity of Oxford34
进行中（未招募）
1 期
Dasiglucagon for Prevention of Low Blood Glucose Levels in People with Type 1 DiabetesType 1 diabetesMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2020-000551-12-DKSteno Diabetes Center Copenhagen20
进行中（未招募）
1 期
The HYPO-AVOID STUDY: Low-dose Glucagon and Advanced Insulin pump for Prevention of Exercise-Induced Low Blood Glucose Levels in People with Type 1 DiabetesMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 DiabetesEUCTR2021-004993-68-DKSteno Diabetes Center Copenhagen16